19-base pair deletion polymorphism of the dihydrofolate reductase (DHFR) gene
maternal risk of Down syndrome and folate metabolism
Keywords:
Down syndrome, Polymorphism, genetic, Folic acid, Nondisjunction, genetic, Risk factorsAbstract
CONTEXT AND OBJECTIVE: Polymorphisms in genes involved in folate metabolism may modulate the maternal risk of Down syndrome (DS). This study evaluated the influence of a 19-base pair (bp) deletion polymorphism in intron-1 of the dihydrofolate reductase (DHFR) gene on the maternal risk of DS, and investigated the association between this polymorphism and variations in the concentrations of serum folate and plasma homocysteine (Hcy) and plasma methylmalonic acid (MMA). DESIGN AND SETTING: Analytical cross-sectional study carried out at Faculdade de Medicina de São José do Rio Preto (Famerp). METHODS: 105 mothers of individuals with free trisomy of chromosome 21, and 184 control mothers were evaluated. Molecular analysis on the polymorphism was performed using the polymerase chain reaction (PCR) through differences in the sizes of fragments. Folate was quantified by means of chemiluminescence, and Hcy and MMA by means of liquid chromatography and sequential mass spectrometry. RESULTS: There was no difference between the groups in relation to allele and genotype frequencies (P = 0.44; P = 0.69, respectively). The folate, Hcy and MMA concentrations did not differ significantly between the groups, in relation to genotypes (P > 0.05). CONCLUSIONS: The 19-bp deletion polymorphism of DHFR gene was not a maternal risk factor for DS and was not related to variations in the concentrations of serum folate and plasma Hcy and MMA in the study population.
Downloads
References
Freeman SB, Allen EG, Oxford-Wright CL, et al. The National Down Syndrome Project: design and implementation. Public Health Rep. 2007;122(1):62-72.
Ramírez NJ, Belalcázar HM, Yunis JJ, et al. Parental origin, nondisjunction, and recombination of the extra chromosome 21 in Down syndrome: a study in a sample of the Colombian population. Biomedica. 2007;27(1):141-8.
James SJ, Pogribna M, Pogribny IP, et al. Abnormal folate metabolism and mutation in the methylenetetrahydrofolate reductase gene may be maternal risk factors for Down syndrome. Am J Clin Nutr. 1999;70(4):495-501.
Patterson D. Folate metabolism and the risk of Down syndrome. Downs Syndr Res Pract. 2008;12(2)93-7.
Biselli JM, Goloni-Bertollo EM, Zampieri BL, et al. Genetic polymorphisms involved in folate metabolism and elevated plasma concentrations of homocysteine: maternal risk factors for Down syndrome in Brazil. Genet Mol Res. 2008;7(1):33-42.
Meguid NA, Dardir AA, Khass M, et al. MTHFR genetic polymorphism as a risk factor in Egyptian mothers with Down syndrome children. Dis Markers. 2008;24(1):19-26.
Coppedè F, Migheli F, Bargagna S, et al. Association of maternal polymorphisms in folate me- tabolizing genes with chromosome damage and risk of Down syndrome offspring. Neurosci Lett. 2009;449(1):15-9.
Pozzi E, Vergani P, Dalprà L, et al. Maternal polymorphisms for methyltetrahydrofolate reduc- tase and methionine synthetase reductase and risk of children with Down syndrome. Am J Obstet Gynecol. 2009;200(6):636.e1-6.
Stanislawska-Sachadyn A, Brown KS, Mitchell LE, et al. An insertion/deletion polymorphism of the dihydrofolate reductase (DHFR) gene is associated with serum and red blood cell folate concentrations in women. Hum Genet. 2008;123(3):289-95.
Johnson WG, Stenroos ES, Spychala JR, et al. New 19 bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR): a risk factor for spina bifida acting in mothers during pregnancy? Am J Med Genet A. 2004;124A(4):339-45.
Parle-McDermott A, Pangilinan F, Mills JL, et al. The 19-bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR) may decrease rather than increase risk for spina bifida in the Irish population. Am J Med Genet A. 2007;143A(11):1174-80.
Xu X, Gammon MD, Wetmur JG, et al. A functional 19-base pair deletion polymorphism of dihydrofolate reductase (DHFR) and risk of breast cancer in multivitamin users. Am J Clin Nutr. 2007;85(4):1098-102.
Gellekink H, Blom HJ, van der Linden IJ, den Heijer M. Molecular genetic analysis of the human dihydrofolate reductase gene: relation with plasma total homocysteine, serum and red blood cell folate levels. Eur J Hum Genet. 2007;15(1):103-9.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.
Dulucq S, St-Onge G, Gagné V, et al. DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL. Blood. 2008;111(7):3692-700.
Haddad R, Mendes MA, Höehr NF, Eberlin MN. Amino acid quantitation in aqueous matrices via trap and release membrane introduction mass spectrometry: homocysteine in human plasma. Analyst. 2001;126(8):1212-5.
de Andrade CR, Fukada SY, Olivon VC, et al. Alpha1D-adrenoceptor-induced relaxation on rat carotid artery is impaired during the endothelial dysfunction evoked in the early stages of hyperhomocysteinemia. Eur J Pharmacol. 2006;543(1-3):83-91.
Carvalho VM, Kok F. Determination of serum methylmalonic acid by alkylative extraction and li- quid chromatography coupled to tandem mass spectrometry. Anal Biochem. 2008;381(1):67- 73.
Fenech M. The role of folic acid and Vitamin B12 in genomic stability of human cells. Mutat Res. 2001;475(1-2):57-67.
Wang X, Thomas P, Xue J, Fenech M. Folate deficiency induces aneuploidy in human lym- phocytes in vitro-evidence using cytokinesis-blocked cells and probes specific for chromoso- mes 17 and 21. Mutat Res. 2004;551(1-2):167-80.
Beetstra S, Thomas P, Salisbury C, Turner J, Fenech M. Folic acid deficiency increases chromo- somal instability, chromosome 21 aneuploidy and sensitivity to radiation-induced micronuclei. Mutat Res. 2005;578(1-2):317–26.
Finkelstein JD, Martin JJ. Homocysteine. Int J Biochem Cell Biol. 2000;32(4):385-9.
Coppedè F, Marini G, Bargagna S, et al. Folate gene polymorphisms and the risk of Down syndrome pregnancies in young Italian women. Am J Med Genet A. 2006;140(10):1083-91.
Wang SS, Qiao FY, Feng L, Lv JJ. Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome in China. J Zhejiang Univ Sci B. 2008;9(2):93-9.
Kalmbach RD, Choumenkovitch SF, Troen AP, et al. A 19-base pair deletion polymorphism in dihydrofolate reductase is associated with increased unmetabolized folic acid in plasma and decreased red blood cell folate. J Nutr. 2008;138(12):2323-7.
van der Linden IJ, Nguyen U, Heil SG, et al. Variation and expression of dihydrofolate reductase (DHFR) in relation to spina bifida. Mol Genet Metab. 2007;91(1):98-103.
Barkai G, Arbuzova S, Berkenstadt M, Heifetz S, Cuckle H. Frequency of Down’s syndrome and neural tube defects in the same family. Lancet. 2003;361(9366):1331-5.
Guéant JL, Guéant-Rodriguez RM, Anello G, et al. Genetic determinants of folate and vitamin B12 metabolism: a common pathway in neural tube defect and Down syndrome? Clin Chem Lab Med. 2003;41(11):1473-7.
Klee GG. Cobalamin and folate evaluation: measurement of methylmalonic acid and ho- mocysteine vs vitamin B(12) and folate. Clin Chem. 2000;46(8 Pt 2):1277-83.
Galloway M, Rushworth L. Red cell or serum folate? Results from the National Pathology Alliance benchmarking review. J Clin Pathol. 2003;56(12):924-6.
Bunduki V, Dommergues M, Zittoun J, et al. Maternal-fetal folate status and neural tube de- fects: a case control study. Biol Neonate. 1995;67(3):154-9.
Kilbride J, Baker TG, Parapia LA, Khoury SA. Iron status, serum folate and B(12) values in preg- nancy and postpartum: report from a study in Jordan. Ann Saudi Med. 2000;20(5-6):371-6.
Zhang T, Xin R, Gu X, et al. Maternal serum vitamin B12, folate and homocysteine and the risk of neural tube defects in the offspring in a high-risk area of China. Public Health Nutr. 2009;12(5):680-6.
Eser B, Cosar M, Eser O, et al. 677C>T and 1298A>C polymorphisms of methylenetetrahydro- pholate reductase gene and biochemical parameters in Turkish population with spina bifida occulta. Turk Neurosurg. 2010;20(1):9-15.
